Gossamer Bio, Inc. (GOSS) Insider Trading Activity
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $57M |
GOSS Insider Trading Activity
GOSS Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $324,442 | 3 | 75 |
Sells | $1,260 | 1 | 25 |
Related Transactions
| Hasnain Faheem | President & CEO | 1 | $250,282 | 0 | $0 | $250,282 |
| Giraudo Bryan | COO/CFO | 1 | $59,110 | 0 | $0 | $59,110 |
| Smith Robert Paul JR | Chief Commercial Officer | 1 | $15,050 | 0 | $0 | $15,050 |
| Aranda Richard | Chief Medical Officer | 0 | $0 | 1 | $1,260 | $-1,260 |
About Gossamer Bio, Inc.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
Insider Activity of Gossamer Bio, Inc.
Over the last 12 months, insiders at Gossamer Bio, Inc. have bought $324,442 and sold $1,260 worth of Gossamer Bio, Inc. stock.
On average, over the past 5 years, insiders at Gossamer Bio, Inc. have bought $969,539 and sold $229,726 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Hasnain Faheem (President & CEO) — $250,282. Giraudo Bryan (COO/CFO) — $59,110. Smith Robert Paul JR (Chief Commercial Officer) — $15,050.
The last purchase of 372,000 shares for transaction amount of $250,282 was made by Hasnain Faheem (President & CEO) on 2024‑06‑21.
List of Insider Buy and Sell Transactions, Gossamer Bio, Inc.
| 2024-06-24 | Sale | Aranda Richard | Chief Medical Officer | 1,908 0.0007% | $0.66 | $1,260 | +14.01% | |
| 2024-06-21 | Hasnain Faheem | President & CEO | 372,000 0.2168% | $0.67 | $250,282 | +44.86% | ||
| 2024-06-18 | Giraudo Bryan | COO/CFO | 100,000 0.0512% | $0.59 | $59,110 | +73.53% | ||
| 2024-06-17 | Smith Robert Paul JR | Chief Commercial Officer | 25,000 0.013% | $0.60 | $15,050 | +80.95% | ||
| 2024-03-27 | Sale | Christian Waage | EVP, Tech Ops and Admin | 6,430 0.0028% | $1.16 | $7,430 | -22.01% | |
| 2024-03-27 | Sale | Hasnain Faheem | President & CEO | 23,172 0.0101% | $1.16 | $26,773 | -22.01% | |
| 2024-03-27 | Sale | Giraudo Bryan | COO/CFO | 6,430 0.0028% | $1.16 | $7,431 | -22.01% | |
| 2024-03-18 | Sale | Aranda Richard | Chief Medical Officer | 4,018 0.0017% | $1.33 | $5,342 | -33.88% | |
| 2024-03-18 | Sale | Peterson Caryn | EVP, Regulatory Affairs | 4,018 0.0017% | $1.33 | $5,343 | -33.88% | |
| 2023-11-15 | Milligan Sandra | director | 32,000 0.0139% | $0.79 | $25,213 | +11.07% | ||
| 2023-11-13 | Giraudo Bryan | COO/CFO | 200,000 0.0795% | $0.56 | $112,880 | +43.00% | ||
| 2023-06-22 | Sale | Aranda Richard | Chief Medical Officer | 1,814 0.0018% | $1.29 | $2,340 | -34.61% | |
| 2023-04-04 | Giraudo Bryan | COO/CFO | 55,000 0.0583% | $1.02 | $56,095 | +3.96% | ||
| 2023-03-16 | Sale | Aranda Richard | Chief Medical Officer | 7,563 0.0083% | $1.10 | $8,304 | 0.00% | |
| 2023-03-16 | Sale | Carter Laura | Chief Scientific Officer | 6,029 0.0066% | $1.10 | $6,620 | 0.00% | |
| 2023-03-16 | Sale | Peterson Caryn | EVP, Regulatory Affairs | 7,564 0.0083% | $1.10 | $8,305 | 0.00% | |
| 2022-10-24 | Sale | Aranda Richard | Chief Medical Officer | 4,757 0.0056% | $12.07 | $57,431 | -88.98% | |
| 2022-10-24 | Sale | Carter Laura | Chief Scientific Officer | 4,876 0.0058% | $12.07 | $58,868 | -88.98% | |
| 2022-10-24 | Sale | Peterson Caryn | EVP, Regulatory Affairs | 4,757 0.0056% | $12.07 | $57,431 | -88.98% | |
| 2022-07-15 | Hasnain Faheem | President & CEO | 138,696 0.099% | $7.21 | $999,998 | -79.92% |
Insider Historical Profitability
| Hasnain Faheem | President & CEO | 5408073 2.3801% | $5.62M | 4 | 2 | <0.0001% |
| Giraudo Bryan | COO/CFO | 480010 0.2113% | $499,210.40 | 9 | 3 | +0.58% |
| Aranda Richard | Chief Medical Officer | 196891 0.0867% | $204,766.64 | 0 | 8 | |
| Smith Robert Paul JR | Chief Commercial Officer | 25000 0.011% | $26,000.00 | 1 | 0 | |
| Omega Fund V, L.P. | 10 percent owner | 6553416 2.8842% | $6.82M | 0 | 8 | |
| Gujrathi Sheila | President & CEO | 4048242 1.7816% | $4.21M | 1 | 0 | <0.0001% |
| Christian Waage | EVP, Tech Ops and Admin | 585934 0.2579% | $609,371.36 | 4 | 3 | <0.0001% |
| Salter-Cid Luisa | Chief Scientific Officer | 206065 0.0907% | $214,307.60 | 0 | 3 | |
| Carter Laura | Chief Scientific Officer | 76263 0.0336% | $79,313.52 | 1 | 6 | |
| Peterson Caryn | EVP, Regulatory Affairs | 49833 0.0219% | $51,826.32 | 0 | 5 | |
| Milligan Sandra | director | 32000 0.0141% | $33,280.00 | 1 | 0 | +11.07% |
| Cox Russell J. | director | 7200 0.0032% | $7,488.00 | 1 | 0 | +6.27% |
| Dupont Jakob | Chief Medical Officer | 0 0% | $0 | 0 | 2 |
Historical Insider Profitability vs. Competitors
$144,247,213 | 29 | 10.15% | $255.02M | |
$56,550,550 | 22 | 50.17% | $251.53M | |
$14,865,077 | 18 | -28.56% | $268.05M | |
$2,484,989 | 17 | -17.86% | $221.48M | |
$1,345,573 | 16 | 15.45% | $219.08M | |
$276,750,010 | 16 | -7.95% | $244.81M | |
Gossamer Bio, Inc. (GOSS) | $3,232,510 | 15 | -2.42% | $236.31M |
$57,263,116 | 11 | -8.37% | $242.79M | |
$58,981,940 | 10 | 32.58% | $220.53M | |
$15,297,672 | 8 | -17.63% | $266.14M | |
$14,995,689 | 8 | 3.76% | $245.17M | |
$334,190 | 8 | 33.75% | $236.09M | |
$214,493 | 7 | -84.84% | $241.69M | |
$51,588,185 | 5 | 19.18% | $223.48M | |
$12,010,220 | 4 | -72.15% | $227.24M | |
$79,238,118 | 4 | -26.47% | $214.68M | |
$4,888,000 | 3 | -20.50% | $246.93M | |
$102,796 | 1 | -21.40% | $234.49M | |
$879,499 | 1 | 28.50% | $233.76M |
GOSS Institutional Investors: Active Positions
| Increased Positions | 42 | +35.29% | 21M | +12.4% |
| Decreased Positions | 45 | -37.82% | 22M | -12.67% |
| New Positions | 11 | New | 1M | New |
| Sold Out Positions | 16 | Sold Out | 2M | Sold Out |
| Total Postitions | 116 | -2.52% | 171M | -0.28% |
GOSS Ownership Change vs Market
Institutional Investor Ownership
| Octagon Capital Advisors Lp | $21,653.00 | 8.08% | 18.35M | +9M | +99.72% | 2024-12-31 |
| Nea Management Company, Llc | $21,350.00 | 7.97% | 18.09M | 0 | 0% | 2024-12-31 |
| Vanguard Group Inc | $11,840.00 | 4.42% | 10.03M | -2M | -14.63% | 2024-12-31 |
| Alyeska Investment Group, L.P. | $10,394.00 | 3.88% | 8.81M | +3M | +52.73% | 2024-12-31 |
| Arch Venture Management, Llc | $9,506.00 | 3.55% | 8.06M | 0 | 0% | 2024-12-31 |
| Fmr Llc | $9,361.00 | 3.5% | 7.93M | -2,735 | -0.03% | 2024-12-31 |
| 683 Capital Management, Llc | $8,231.00 | 3.07% | 6.97M | +1M | +20.26% | 2024-12-31 |
| Palo Alto Investors Lp | $7,407.00 | 2.77% | 6.28M | 0 | 0% | 2024-12-31 |
| Silverarc Capital Management, Llc | $7,283.00 | 2.72% | 6.17M | +526,495 | +9.33% | 2024-12-31 |
| Samsara Biocapital, Llc | $7,234.00 | 2.7% | 6.13M | 0 | 0% | 2024-12-31 |